Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor and EMT-Driven Cancer Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FZD2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FZD2 ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View FZD2 Products |
| Gene Delivery | FZD2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Crucial for GPCR native conformation. |
View FZD2 Products |
| Benchmark Ab | Pan-FZD Antibody (Sequence of Vantictumab) Recombinant positive control. (Note: Binds multiple FZD receptors). |
View FZD2 Products |
| Validator | FZD2 siRNA Set For knockdown verification. |
View FZD2 Products |
| Related Target A | WNT5A Key non-canonical Wnt pathway ligand for FZD2. |
View WNT5A Products |
| Related Target B | ROR1 Co-receptor in Wnt signaling, synergistic targeting potential. |
View ROR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation & Presentation | Lentivirus Premade Particles for stable cell line construction, preserving 7-TM structure. |
| Frizzled Family Cross-Reactivity (FZD1-10) | Sequence Verified ECD-Fc proteins for counter-screening and precise selectivity profiling. |
| Lack of Specific Controls | Pan-FZD Benchmark Antibodies included for broad-spectrum positive binding reference. |
| False Positives in Cell Assays | Validated siRNA included for rigorous specificity checks and target validation. |
Live FZD2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FZD2 therapeutics is intensifying, with major players shifting focus from broad Pan-FZD mAbs to highly specific FZD2-targeted modalities. As first-generation therapies (which faced challenges like bone toxicity due to off-target Wnt inhibition) reach clinical re-evaluation, the next wave of R&D is targeting precise ADCs and bispecifics to maximize tumor specificity and minimize systemic side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-FZD mAb | OncoMed (Historical) | Solid Tumors | Selectivity Assay (Need Homolog panel proteins) |
| FZD2 Specific mAb/ADC | Emerging Biotechs | HCC, Breast Cancer | Internalization Assay (Need Lentivirus cell lines) |
| Bispecific (FZD2 x CD3) | Preclinical R&D | Refractory Tumors | Heterodimer Validation (Need High-purity ECD-Fc) |